Premium
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
Author(s) -
Vruchte Danielle,
Sturchio Andrea,
Priestman David A.,
Tsitsi Panagiota,
Hertz Ellen,
Andréasson Mattias,
Markaki Ioanna,
Wallom KerriLee,
Platt Frances,
Svenningsson Per
Publication year - 2022
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.29163
Subject(s) - glycosphingolipid , parkinson's disease , disease , glycolipid , movement disorders , medicine , psychology , endocrinology , neuroscience , chemistry , biochemistry
Background Alteration in glycosphingolipids (GSLs) in Parkinson's disease (PD) still needs to be determined. Objectives We evaluated if PD subjects show abnormal GSLs levels compared to healthy controls (HC) and if GSLs correlate with clinical features. Methods We analyzed GSLs and glucosylceramide (GlcCer) in plasma using two normal‐phase high‐performance liquid chromatography assays; clinico‐demographic data were extracted. Results Eighty PD subjects and 25 HCs were analyzed. Levels of GlcCer, GD1b, Gb4, GalNAcGA1, and b‐series were higher in PD patients than in HCs; total GSLs, GT1b, GM1a, GM3, GM2, and a‐series levels were lower in PD patients than in HCs. Changes in GSLs were present in PD subjects, with GlcCer levels similar to those in HCs. The results were similar after excluding certain GBA1 mutation carriers. Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III, correlated with Gb4 and Montreal Cognitive Assessment with GD1b levels. Conclusions Multiple GSL abnormalities in plasma were detected in patients with and without GlcCer changes, indicating a broader shift in lipid homeostasis. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.